OncoStem Diagnostics and Dr. Manjiri Bakre in the news
Women’s Entrepreneur Review; Women Leaders In Healthcare Publication Date: October 2024 Issue
+ Read MorePrognostic test, like CanAssist Breast, helps personalize treatment strategies based on the aggressive biology of the tumor and the likelihood of recurrence, ensuring patients receive the optimal treatment with minimum side effects.
By understanding cancer behavior at the cellular/molecular level, prognostic testing helps optimize treatment decisions, leading to better outcomes and more efficient use of healthcare resources.
In the era of precision medicine, OncoStem aims to deliver cutting-edge technology to assist physicians in providing cost-effective, personalized treatment choices for cancer patients. OncoStem’s team of scientists has developed innovative one-of-a-kind multi-marker prognostic test for breast cancer- CanAssist Breast- that provides information regarding a patient’s cancer recurrence risk.
CanAssist Breast (CAB) uses a combination of proteomics and an AI-based approach. CAB assesses the expression of five cancer biomarkers using an automated IHC platform and further integrates it with clinical parameters in a proprietary AI-based algorithm to determine the risk of distant cancer recurrence in patients. This pioneering test, made in India in 2016, has since expanded its reach across multiple countries, including India, Turkey, UAE, Saudi Arabia, Sri Lanka, Bangladesh, and Iran, helping clinicians worldwide make informed decisions for personalized breast cancer treatment.
Women’s Entrepreneur Review; Women Leaders In Healthcare Publication Date: October 2024 Issue
+ Read MoreCanAssist Breast employs a comprehensive biomarker analysis technique to arrive at its prognostic score. This process delves into the complex molecular structure of the patient's tumor, enabling a more personalized approach to breast cancer management.
Know MoreCanAssist Breast evaluates multiple biomarkers in the tumor tissue, providing a deeper understanding of the tumor's specific characteristics for personalized treatment.
The test generates a risk score based on biomarker data, predicting the likelihood of cancer recurrence within five years, allowing for tailored treatment strategies.
By identifying low-risk patients, CanAssist Breast helps avoid unnecessary aggressive treatments, reducing side effects and healthcare costs.
The test ensures that high-risk patients receive aggressive therapies at the appropriate time, improving their chances of successful treatment.